Damora Therapeutics (DMRA) Other Gross PP&E Adjustments (2019 - 2025)
Damora Therapeutics posted quarterly Other Gross PP&E Adjustments of -$874000.0 for Q4 2025, down 22.41% year-on-year from -$1.1 million in Q4 2024, and down 2527.78% on a QoQ basis from $36000.0 in Q3 2025.
Damora Therapeutics (DMRA) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$874000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments fell 22.41% year-over-year to -$874000.0; the trailing twelve-month figure through Dec 2025 stood at -$874000.0 (down 22.41% YoY), and the FY2025 full-year result was -$874000.0, down 22.41% from the prior year.
- Other Gross PP&E Adjustments for Q4 2025 stood at -$874000.0, down from $36000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $75000.0 in Q3 2024 and bottomed at -$943000.0 in Q4 2023.
- The 5-year median for Other Gross PP&E Adjustments is -$352500.0 (2022), against an average of -$378900.0.
- The widest annual swing landed in 2023, when Other Gross PP&E Adjustments tumbled 141.18%; it then soared 426.09% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$611000.0 in 2021, then surged by 36.01% to -$391000.0 in 2022, then plunged by 141.18% to -$943000.0 in 2023, then increased by 24.28% to -$714000.0 in 2024, then slipped by 22.41% to -$874000.0 in 2025.
- The last three Other Gross PP&E Adjustments figures came in at -$874000.0 (Q4 2025), $36000.0 (Q3 2025), and $33000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -874,000.00 |
| Dec 31, 2025 | -874,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | -714,000.00 |
| Dec 31, 2024 | -714,000.00 |
| Sep 30, 2024 | 75,000.00 |
| Sep 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Dec 31, 2023 | -943,000.00 |
| Dec 31, 2023 | -943,000.00 |
| Sep 30, 2023 | -23,000.00 |
| Sep 30, 2023 | -23,000.00 |
| Jun 30, 2023 | -208,000.00 |
| Jun 30, 2023 | -208,000.00 |
| Mar 31, 2023 | -279,000.00 |
| Mar 31, 2023 | -279,000.00 |
| Dec 31, 2022 | -391,000.00 |
| Dec 31, 2022 | -391,000.00 |
| Sep 30, 2022 | -473,000.00 |
| Sep 30, 2022 | -473,000.00 |
| Jun 30, 2022 | -314,000.00 |
| Jun 30, 2022 | -314,000.00 |
| Mar 31, 2022 | -436,000.00 |
| Mar 31, 2022 | -436,000.00 |
| Dec 31, 2021 | -611,000.00 |
| Dec 31, 2021 | -611,000.00 |
| Sep 30, 2021 | -713,000.00 |
| Sep 30, 2021 | -713,000.00 |
| Jun 30, 2021 | -894,000.00 |
| Jun 30, 2021 | -894,000.00 |
| Mar 31, 2021 | -868,000.00 |
| Mar 31, 2021 | -868,000.00 |
| Dec 31, 2020 | -885,000.00 |
| Dec 31, 2020 | -885,000.00 |
| Sep 30, 2020 | -905,000.00 |
| Sep 30, 2020 | -905,000.00 |
| Dec 31, 2019 | -298,000.00 |
| Dec 31, 2019 | -298,000.00 |